Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) has signed a definitive agreement to acquire ZuriMED, a privately held developer of the commercialized FiberLocker System, a soft tissue augmentation technology for rotator cuff repair. The system is designed to provide a novel rotator cuff augmentation approach with increased biomechanical strength and to reduce a key clinical failure mode in these procedures.
According to Stryker, the deal is intended to strengthen its shoulder portfolio and expand support for shoulder specialists across sports medicine and arthroplasty, particularly in rotator cuff augmentation, described as one of the fastest‑growing areas in sports medicine and a significant opportunity in shoulder care. The transaction is subject to customary closing conditions, and Stryker and ZuriMED will operate as separate entities until closing.
Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference/b) on at Encore Boston Harbor. CFO Preston Wells and VP Investor Relations Nick Mead will join a fireside chat at 2:15 p.m. Eastern time, accessible via live audio webcast and replay on Stryker’s Events & Presentations page.
Providence Medical Technology appointed Lane Major as President & Chief Executive Officer, effective August 6, 2026, and added him to the Board of Directors. The company highlights strong commercial momentum for its CORUS tissue-sparing fusion platform across cervical and lumbar markets, including navigated solutions that integrate with leading surgical navigation systems.
Major brings over 25 years of spine and medical device leadership, including co-founding K2M, guiding it through a 2014 IPO (NASDAQ: KTWO) and a $1.4 billion acquisition by Stryker (NYSE: SYK). At Stryker, he led the Global Spine Business, overseeing roughly $2 billion in investments across more than 40 countries. According to Providence, its TSF platform is supported by Level 1 clinical data, which Major is expected to help further scale.
Stryker (NYSE:SYK) announced that its Board of Directors declared a quarterly dividend of $0.88 per share, payable on July 31, 2026 to shareholders of record as of the close of business on June 30, 2026. The dividend represents a 4.8% increase versus the prior year and is unchanged from the previous quarter, indicating continued cash returns to shareholders.
Stryker (NYSE:SYK) reported second quarter 2026 net sales of $6.6 billion, up 9.4% as reported and 9.0% in constant currency, with organic net sales up 9.0%. MedSurg and Neurotechnology sales rose 9.7% to $3.6 billion, and Orthopaedics sales grew 9.1% to $3.0 billion.
Reported operating income margin was 25.2% and adjusted operating income margin(1) increased 170 bps to 27.4%. Reported EPS increased to $3.30, while adjusted EPS(1) rose 17.9% to $3.69. Net earnings were $1.3 billion, up 44.3%. Operating cash flow for the first half of 2026 was $1.8 billion, compared with $1.4 billion in 2025.
For full year 2026, Stryker now expects organic net sales growth(2) of 8.3%–9.3% and adjusted EPS(2) of $14.95–$15.10, including a modestly positive pricing impact and a slightly favorable expected foreign exchange effect if rates remain near current levels.
Stryker (NYSE: SYK) announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement on July 16, 2026. The system debuts the Mako Handheld Robotics platform, extending the Mako portfolio beyond robotic-arm assisted surgery into a new orthopaedic robotics category.
Mako RPS combines intraoperative planning with a robotically enabled saw and Stryker’s patented active adjustment technology, designed to respond to surgeons’ hand movements and help maintain alignment with the surgical plan. It is compatible with Stryker’s Triathlon Total Knee System and built to work with the Q Guidance System, expanding Stryker’s enabling technologies ecosystem.
Stryker (NYSE: SYK) will host a live webcast at 4:30 p.m. ET on Thursday, July 30, 2026 to discuss its second quarter 2026 financial results.
An accompanying earnings press release will be issued at approximately 4:05 p.m. ET, with both webcast and archive available on Stryker’s website.
Stryker (NYSE:SYK) announced a partnership with Major Champion golfer Shane Lowry as brand ambassador for its Joint Replacement division. Lowry, who supported his father through hip and knee replacements, will help spotlight the caregiver role in joint pain, surgery and recovery.
A global campaign across media, social and educational channels will focus on awareness, education and access to information for caregivers, encouraging proactive involvement from understanding treatment options to navigating recovery. Fans at the Travelers Championship can learn about joint pain treatment options in Stryker’s Fan Zone.
Stryker (NYSE:SYK) launched TPX HD, a premium small bone power tool for demanding orthopaedic procedures, including total joint revisions, minimally invasive surgery and oral maxillofacial cases.
The system offers up to 296% more torque and 40% faster performance* versus TPX Micro Drill at high speed, plus improved visibility, heat management and ergonomics.
Stryker (NYSE:SYK) launched its Pangea Plating System in Europe for treating a wide range of fracture patterns. The first European clinical case was completed at St. George's University Hospital in London.
The system offers anatomically focused plates, streamlined instrumentation, and variable-angle plating for fracture fixation across upper and lower extremities, and was developed with input from 26 orthopaedic surgeons using global anatomical data.